Exhibit 1
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned company and individuals agree to the joint filing on behalf of each of them of a Schedule 13D (including amendments thereto) with respect to the Common Stock of Xenetic Biosciences, Inc. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
| June 14, 2023 | |
| Date | |
| CLS Therapeutics, LLC. | |
| /s/ Georgy Tets | |
| Signature | |
| Georgy Tets, MD, PhD, Chief Executive Officer | |
| Name/Title | |
| CLS Therapeutics, LLC | |
| /s/ Georgy Tets | |
| Signature | |
| Georgy Tets, MD, PhD, Director | |
| Name/Title | |
| /s/ Dmitry Genkin | |
| Signature | |
| Dmitry Genkin | |
| Name | |
| /s/ Victor Tets | |
| Signature | |
| Victor Tets | |
| Name | |
| /s/ Georgy Tets | |
| Signature | |
| Georgy Tets, MD, PhD | |
| Name | |
| /s/ M. Scott Maguire | |
| Signature | |
| M. Scot Maguire | |
| Name |
